Ignite Creation Date:
2024-05-06 @ 7:51 PM
Last Modification Date:
2024-10-26 @ 3:15 PM
Study NCT ID:
NCT06159803
Status:
RECRUITING
Last Update Posted:
2024-04-17
First Post:
2023-10-17
Brief Title:
LIving BEtteR With asThma - Intervention Development Study
Sponsor:
University Hospital Southampton NHS Foundation Trust
Organization:
University Hospital Southampton NHS Foundation Trust
Study Overview
Official Title:
LIving BEtteR With asThma - Intervention Development Study
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LIBERTY-ID
Brief Summary:
Approximately 330 million people in the world are living with asthma and 3-10 of them has difficult asthma that is challenging to control even with maximum doses of pharmacological treatment In the last five years our multidisciplinary team has shown the clinical benefits of a short-term structured exercise programme for people living with difficult asthma PDA 1 However engaging PDA in self-maintained exercise long-term and outside of the hospital environment remains a challenge Changing and maintaining behaviours requires complex psychological and cognitive processes and appropriate modes of support by skilled practitioners Underpinned by behavioural science and health psychology principles our team has developed a world renown multimodal self-management support intervention for people living with cancer 2 The intervention focuses on initiating and maintaining exercise optimising diet and includes supporting people through the cognitive and psychological processes to change their behaviour We aim to adapt this intervention for PDA to optimise their self-management via the LIBERTY study To achieve the best outcomes prior to commencing the LIBERTY study we aim to develop the intervention using the acclaimed Person-Based Approach PBA 3 This methodology is considered gold standard in behaviour change intervention development implementation and evaluation and maximise the probability of the uptake and maintenance of the desired behaviour
Detailed Description:
The burden of poor asthma control remains high in the United Kingdom UK Given high asthma prevalence poor asthma control exerts significant impact at individual and societal levels and accounts for one fifth of the total chronic respiratory disability-adjusted life year burden 4 Remission or well-controlled asthma requires continuation of regular medical treatment sustained adherence to medications and other self-management behaviours eg healthy diet avoiding triggers physical activity and exposure to risk of potential medication side effects with plus ongoing financial implications 3-10 of people living with asthma has difficult asthma defined as asthma that is uncontrolled despite GINA Global Initiative for Asthma Step 4 or 5 treatment 5 or requires such treatment to maintain good control and reduce exacerbations It is increasingly recognised that problematic difficult asthma is a multidimensional state comprising numerous treatable traits that merit targeted approaches 6 This multimorbid disease framework defined as the coexistence of 2 health conditions is particularly prevalent in difficult asthma and represents a complex constellation of conditions that collectively impose a significant burden on the patient 7 These treatable traits can be pulmonary extrapulmonary and behavioural 7 Treatable traits including obesity anxiety and depression dysfunctional breathing and inactivity predict future exacerbation risk in difficult asthma and so addressing these should be a key part of asthma management for both individual patient benefit and health economic reasons 8 Multimodal non-pharmacological approaches are needed to do that but there is limited understanding of their role in difficult asthma to guide their use
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None